Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19110477,overall recoveries,The overall recoveries for ALV and PHA were 83.5% and 86.2% respectively.,Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19110477/),%,83.5,188950,DB01616,Alverine
,19110477,overall recoveries,The overall recoveries for ALV and PHA were 83.5% and 86.2% respectively.,Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19110477/),%,86.2,188951,DB01616,Alverine
,19110477,Total elution time,Total elution time was about 4 min which allowed quantitation of more than 150 plasma samples per day.,Validated LC-MS/MS method for determination of Alverine and one of its hydroxy metabolites in human plasma along with its application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19110477/),min,4,188952,DB01616,Alverine
,20564607,total run time,"Chromatographic separation was carried out on a Hypersil GOLD C(18) column (50 mm x 4.6 mm, 5 microm) with an isocratic mobile phase and a total run time of 1.5 min.","A rapid and most sensitive liquid chromatography/tandem mass spectrometry method for simultaneous determination of alverine and its major metabolite, para hydroxy alverine, in human plasma: application to a pharmacokinetic and bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20564607/),min,1.5,226277,DB01616,Alverine
